Literature DB >> 20028710

Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.

A S Drake1, B Weinstock-Guttman, S A Morrow, D Hojnacki, F E Munschauer, R H B Benedict.   

Abstract

The MS Functional Composite (MSFC) is a continuous scale of neurological disability for patients with multiple sclerosis (MS). Cognition is represented by the Paced Auditory Serial Addition Test (PASAT), although the Symbol Digit Modalities Test (SDMT) has been proposed as a promising alternative. MSFC scores were calculated using either the PASAT or the SDMT with the following reference populations: National Multiple Sclerosis Society (NMSS) Task Force, 400 MS patients, and 100 normal controls. A subgroup of 115 patients was followed longitudinally, with a test-retest interval of 2.3 +/- 1.2 years. Pearson correlations were calculated and analyses of variance (ANOVAs) were used to assess relationships among the MSFC components and composite scores, and differences in performance between patients and controls. Longitudinal changes were also assessed. Logistic regression was performed to determine which MSFC scores are most predictive of diagnosis, course, and work disability. All MSFCs had similar test-retest reliability and correlations with other measures including neurological disability, depression, and fatigue. The SDMT showed slightly better validity with respect to predicting diagnosis, course, and work disability, although the amount of variance accounted for was similar for each version of the MSFC. Our data, derived from a large sample of MS patients and normal controls, supports the validity of both PASAT and SDMT versions of the MSFC. Because the SDMT has slightly better predictive validity and has a relatively easier administration procedure, some clinicians and researchers may wish to replace the PASAT with the SDMT in future calculations of the MSFC using the calculation methods provided in this manuscript.

Entities:  

Mesh:

Year:  2009        PMID: 20028710     DOI: 10.1177/1352458509354552

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  64 in total

1.  Validity of a computerized version of the symbol digit modalities test in multiple sclerosis.

Authors:  Nadine Akbar; Kimia Honarmand; Nancy Kou; Anthony Feinstein
Journal:  J Neurol       Date:  2010-10-06       Impact factor: 4.849

2.  Normal-appearing white matter permeability distinguishes poor cognitive performance in processing speed and working memory.

Authors:  A Eilaghi; A Kassner; I Sitartchouk; P L Francis; R Jakubovic; A Feinstein; R I Aviv
Journal:  AJNR Am J Neuroradiol       Date:  2013-05-30       Impact factor: 3.825

3.  Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world.

Authors:  Myla D Goldman; Robert W Motl; John Scagnelli; John H Pula; Jacob J Sosnoff; Diego Cadavid
Journal:  Neurology       Date:  2013-10-30       Impact factor: 9.910

4.  Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.

Authors:  Amy Perrin Ross; June Halper; Colleen J Harris
Journal:  Int J MS Care       Date:  2012

5.  Tests of information processing speed: what do people with multiple sclerosis think about them?

Authors:  Lisa A S Walker; Amy Cheng; Jason Berard; Lindsay I Berrigan; Laura M Rees; Mark S Freedman
Journal:  Int J MS Care       Date:  2012

6.  Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model.

Authors:  Martin Stangel; Iris Katharina Penner; Boris A Kallmann; Carsten Lukas; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2015-01       Impact factor: 6.570

7.  Analysis of "task-positive" and "task-negative" functional networks during the performance of the Symbol Digit Modalities Test in patients at presentation with clinically isolated syndrome suggestive of multiple sclerosis.

Authors:  C Forn; M A Rocca; I Boscá; B Casanova; A Sanjuan; M Filippi
Journal:  Exp Brain Res       Date:  2013-01-04       Impact factor: 1.972

8.  The computer-based Symbol Digit Modalities Test: establishing age-expected performance in healthy controls and evaluation of pediatric MS patients.

Authors:  Sandra Bigi; R A Marrie; C Till; E A Yeh; N Akbar; A Feinstein; B L Banwell
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

9.  Randomized controlled trial of physical activity, cognition, and walking in multiple sclerosis.

Authors:  Brian M Sandroff; Rachel E Klaren; Lara A Pilutti; Deirdre Dlugonski; Ralph H B Benedict; Robert W Motl
Journal:  J Neurol       Date:  2013-12-10       Impact factor: 4.849

10.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Authors:  Robert J Fox; Christopher S Coffey; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robin Conwit; Robert Naismith; Akshata Ashokkumar; Robert Bermel; Dixie Ecklund; Maxine Koepp; Jeffrey Long; Sneha Natarajan; Srividya Ramachandran; Thomai Skaramagas; Brenda Thornell; Jon Yankey; Mark Agius; Khurram Bashir; Bruce Cohen; Patricia Coyle; Silvia Delgado; Dana Dewitt; Angela Flores; Barbara Giesser; Myla Goldman; Burk Jubelt; Neil Lava; Sharon Lynch; Augusto Miravalle; Harold Moses; Daniel Ontaneda; Jai Perumal; Michael Racke; Pavle Repovic; Claire Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Gutman; Vijayshree Yadav; Aram Zabeti
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.